Epic Bio to Participate in the BMO Virtual Spotlight Series

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas protein, today announced that the company will be participating in the BMO Virtual Spotlight Series: Epigenome Editing, on November 21, 2022.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, November 15, 2022
Information
Tags: 
Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, AAV, GEMS, Gene expression, Biotechnology, Engineering, Bio, DNA, DCAS, Research, Horizons Ventures, CRISPR, DNA-binding protein, FSHD, A1AD, Facioscapulohumeral muscular dystrophy, Vaccine
Geotags: 
CALIFORNIA, UNITED STATES, NORTH AMERICA
Organisation: 
EPIC BIO
Summary
Key Points: 
  • Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas protein, today announced that the company will be participating in the BMO Virtual Spotlight Series: Epigenome Editing, on November 21, 2022.
  • Amber Salzman, Ph.D., chief executive officer, and Dan Hart, Ph.D., head of technology development, are scheduled to participate in a fireside chat from 11:00 11:25 am ET.
  • Epic Bio is a leading epigenome engineering company leveraging the power of CRISPR without cutting DNA.
  • Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypocholesterolemia (HeFH), as well as other indications.


Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas protein, today announced that the company will be participating in the BMO Virtual Spotlight Series: Epigenome Editing, on November 21, 2022.

Amber Salzman, Ph.D., chief executive officer, and Dan Hart, Ph.D., head of technology development, are scheduled to participate in a fireside chat from 11:00 – 11:25 am ET.

About Epic Bio

Epic Bio is a leading epigenome engineering company leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company’s library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies with delivery via a single AAV vector. Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypocholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epic-bio.com for more information, or follow us on Twitter and LinkedIn.

Copyright: 
Copyright Business Wire 2022